SpringerLink
Log in

Cellular cytotoxic drug sensitivity in children with acute leukemia and Down's syndrome: an explanation to differences in clinical outcome?

  • Correspondence
  • Published:
Leukemia Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Subscribe and save

Springer+ Basic
EUR 32.99 /Month
  • Get 10 units per month
  • Download Article/Chapter or Ebook
  • 1 Unit = 1 Article or 1 Chapter
  • Cancel anytime
Subscribe now

Buy Now

Price includes VAT (Canada)

Instant access to the full article PDF.

Institutional subscriptions

Figure 1

References

  1. Ravindranath Y, Abella E, Krischer JP, Wiley J, Inoue S, Harris M, Chauvenet A, Alvarado CS, Dubowy R, Ritchey AK, Land V, Steuber CP, Weinstein H . Acute myeloid leukemia (AML) in Down's syndrome is highly responsive to chemotherapy: experience on Pediatric Oncology Group AML study 8498 Blood 1992 80: 2210–2214

    CAS  PubMed  Google Scholar 

  2. Lie SO, Jonmundsson G, Mellander L, Siimes M, Yssing M, Gustafsson G . A population-based study of 272 children with acute myeloid leukaemia treated on two consecutive protocols with different intensity: best outcome in girls, infants and children with Down's syndrome Br J Haematol 1996 94: 82–88

    Article  CAS  Google Scholar 

  3. Dördelmann M, Schrappe M, Reiter A, Zimmermann M, Graf N, Schott G, Lampert F, Harbott J, Niemeyer C, Ritter J, Dörffel W, Nessler G, Kuhl J, Riehm H . Down's syndrome in childhood acute lymphoblastic leukemia: clinical characteristics and treatment outcome in four consecutive BFM trials Leukemia 1998 12: 645–651

    Article  Google Scholar 

  4. Glomstein A, Gustafsson G, Clausen N, Saarinen-Pihkala UM, Lie SO . Down's syndrome and acute leukemia in children: a population-based Nordic study Med Ped Oncol 1999 33: 245

    Google Scholar 

  5. Gustafsson G, Kreuger A, Clausen N, Garwicz S, Kristinsson J, Lie SO, Moe PJ, Perkkiö M, Yssing M, Saarinen-Pihkala UM . Intensified treatment of acute childhood lymphoblastic leukemia has improved prognosis, especially in non-high-risk patients: the Nordic experience of 2648 patients diagnosed between 1981 to 1996 Acta Paediatr 1998 87: 1151–1161

    Article  CAS  Google Scholar 

  6. Kaspers GJL, Veerman AJP, Pieters R, Van Zantwijk CH, Smets LA, Van Wering ER, Van Der Does-Van Den Berg A . In vitro cellular drug resistance and prognosis in newly diagnosed childhood acute lymphoblastic leukemia Blood 1998 90: 2723–2729

    Google Scholar 

  7. Nygren P, Kristensen J, Jonsson B, Sundström C, Lönnerholm G, Kreuger A, Larsson R . Feasibility of the fluorometric microculture cytotoxicity assay (FMCA) for cytotoxic drug sensitivity testing of tumor cells from patients with acute lymphoblastic leukemia Leukemia 1992 6: 1121–1128

    CAS  PubMed  Google Scholar 

  8. Taub JW, Stout ML, Buck SA, Huang X, Vega RA, Becton DL, Ravindranath Y . Myeloblasts from Down syndrome children with acute myeloid leukemia have increased in vitro sensitivity to cytosine arabinoside and daunorubicin Leukemia 1997 11: 1594–1595

    Article  CAS  Google Scholar 

  9. Kaspers GJL, Zwaan CM, Ramakers-Van Woerden NL, Pieters R, Wunsche R, Rottier MMA, Hählen K, Janka-Schaub G, Creutzig U, Veerman AJP . Favorable in vitro drug resistance profiles in children with Down syndrome and acute leukemia, both in ALL and AML ASH, Miami 1998 abstr. 1642

Download references

Acknowledgements

This work was supported by Lions’ Cancer Research Foundation in Uppsala and by the Children's Cancer Foundation in Sweden. The contribution of patient samples from members of the Nordic Society of Pediatric Hematology and Oncology (NOPHO) is gratefully acknowledged.

Author information

Authors and Affiliations

  1. Dept of Pediatrics, University Hospital, Uppsala, Sweden

    B-M Frost & G Lönnerholm

  2. Childhood Cancer Research Unit, Karolinska Hospital, Stockholm, Sweden

    G Gustafsson

  3. Dept of Clinical Pharmacology, University Hospital, Uppsala, Sweden

    R Larsson

  4. Dept of Oncology, University Hospital, Uppsala, Sweden

    P Nygren

Authors
  1. B-M Frost
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. G Gustafsson
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. R Larsson
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. P Nygren
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. G Lönnerholm
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Frost, BM., Gustafsson, G., Larsson, R. et al. Cellular cytotoxic drug sensitivity in children with acute leukemia and Down's syndrome: an explanation to differences in clinical outcome?. Leukemia 14, 943–944 (2000). https://doi.org/10.1038/sj.leu.2401753

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.leu.2401753

  • Springer Nature Limited

This article is cited by

Search

Navigation